Abstract
Overview
Introduction
Stroke is one of the top three causes of death and its incidence in the seven
major markets is expected to increase in the next ten years because of an
aging population. Long term disability caused by stroke is a major economic
burden on healthcare systems, current treatment options are limited and
general awareness of stroke is poor.
Scope
Analysis of patient potential, unmet needs and clinical trial design in acute
stroke; Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the R&D pipeline; Detailed profiles of
key compounds in development for use in acute stroke, with forecasts of drug
revenues to 2017; Review of the recent failures in acute stroke (NXY-059 and
NovoSeven)
Highlights
In the setting of acute stroke, a patient' s treatment options and recovery
prospects are a function of time. Therefore any delay related to the
time-to-treatment constitutes a resistor to market entry and uptake for stroke
therapies in the acute care hospital setting.
The R&D landscape is shaped by the need to minimize the commercial risk
associated with developing drugs for the acute-care stroke market - the
majority of the companies contribute only one candidate drug to the acute
stroke pipeline.
The future prognosis for the acute stroke therapy is marred by the long list
of failures, especially of neuroprotectants. Thrombolytics are also plagued by
shortcomings in trial design, which result either in discontinuation of the
drugs, or prolonged development that leads in its turn to the low credibility
of the compounds.
Reasons to Purchase
- Understand clinical and environmental unmet needs in the acute stroke
market based on key opinion leader comments
- Benchmark key late-stage pipeline products against the current market
leader and class comparator;
- Assess the 7 major markets (US, Japan, 5 major EU) sales forecasts of
late-stage pipeline drugs and examine their clinical and commercial potential.
| 
View Cart
